Anthony Adam Rosenberg

Anthony Adam Rosenberg is Chief Executive Officer at TR Advisory Services GmbH since 2015.
He is Chairman at Oculis SA since 2018, Chairman at Cullinan Therapeutics, Inc. since 2020, and Chairman at Oculis Holding AG since 2023.
He serves as Director at Cullinan Mica Corp., SiO2 Medical Products, Inc., and Nuclidium AG.
He is an Independent Non-Executive Director at argenx SE since 2017.
He is Senior Advisor at Kurma Partners SA since 2022.
Former roles include Director at Idenix Pharmaceuticals LLC from 2009 to 2013, Independent Director at Radius Health, Inc. from 2015 to 2020, Managing Director at MPM BioImpact LLC from 2015 to 2020, Independent Director at Cullinan Oncology LLC from 2017 to 2020, Head-Mergers, Acquisitions & Licensing at Novartis International AG from 2012 to 2015, and Global Head-Business Development & Licensing at Novartis Pharmaceuticals Corp.
from 2005 to 2012.
Education includes graduate studies at the University of London and undergraduate studies at the University of Leicester.